This supplement to Federal Practitioner on acute coronary syndrome (ACS), supported by the Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, was developed with the aim of helping primary care providers in federal practice
(especially those within the VA health care system) provide the highest quality care to their patients with ACS. It
is our hope that, after reading this supplement, you will be better prepared to:
The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Quadrant HealthCom Inc., the U.S. government, or any of its agencies. Some of the drugs or classes of drugs discussed in this supplement may not be listed on the VA national formulary or the DoD basic core formulary or addressed in VHA or DoD treatment guidelines. Please review complete prescribing information for specific drugs or drug combinations—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients.
Content of the articles contained in this supplement has been reviewed and approved by the Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership.